Drug Trial Radar · NCT07465224
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Jan 15, 2026
Primary completion
May 28, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324Drug
ALN-4324 will be administered subcutaneously (SC).
PlaceboDrug
Placebo will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in M-valueTime frame: Baseline up to Month 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.